HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies-Reference-Cited by-同舟云学术

HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies

Published:2024-01 Issue:1 Volume:19 Page:106-118
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Udagawa Hibiki,Nilsson Monique B.,Robichaux Jacqulyne P.,He Junqin,Poteete Alissa,Jiang Hong,Heeke Simon,Elamin Yasir Y.,Shibata Yuji,Matsumoto Shingo,Yoh Kiyotaka,Okazaki Shogo,Masuko Takashi,Odintsov Igor,Somwar Romel,Ladanyi Marc,Goto Koichi,Heymach John V.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. The HER family and cancer: emerging molecular mechanisms and therapeutic targets;Sergina;Trends Mol Med,2007

2. HER family in cancer progression: from discovery to 2020 and beyond;Kumar;Adv Cancer Res,2020

3. Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and mTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers;Odintsov;J Thorac Oncol,2021

4. Clinicopathologic features and response to therapy of NRG1 fusion-driven lung cancers: the eNRGy1 global multicenter registry;Drilon;J Clin Oncol,2021

5. CD74-NRG1 fusions in lung adenocarcinoma;Fernandez-Cuesta;Cancer Discov,2014

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New promises and challenges in the treatment of advanced non-small-cell lung cancer;The Lancet;2024-08

2. Analysis on the pathogenesis and treatment progress of NRG1 fusion-positive non-small cell lung cancer;Frontiers in Oncology;2024-06-18